Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is a patient-centric, next-generation AI TechBio company with a strong growth outlook. The company has guided to a positive financial forecast, with expected revenue growth of 23-26% and profitability by 2026. With a solid financial position, a market-leading position in tissue-based CGP testing, and a growing portfolio of products, Caris is well-positioned to capitalize on the rapidly-growing precision oncology market.

Bears say

Caris Life Sciences is a high-risk investment due to its uncertain profitability and significant losses since inception, as well as the potential for substantial indebtedness and the need to raise additional capital. While the company has shown strong operational performance, especially with its recent ASP expansion, there are risks in terms of valuation and competition in the precision oncology space. Additionally, the success of newer tests, such as Caris Detect, remains uncertain and may require the company to continue conserving cash until alternative funding can be arranged.

CAI (CAI) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 11 analysts, CAI (CAI) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.